公开(公告)号：EP2310505A1

公开(公告)日：2011-04-20

申请号：EP09772365.4

申请日：2009-06-25

申请人： Santaris Pharma A/S

发明人： HANSEN, Jens, Bo, Rhode ,  NIELSEN, Niels Fisker

IPC分类号： C12N15/11

CPC分类号： C12N15/111 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/3231 ,  C12N2320/50

摘要： The present invention relates to antidote oligomeric compounds (oligomers), which target nucleotide based therapeutics
in vivo , thereby providing a method of controlling the bioavailability and therefore the therapeutic activity and/or side effects of nucleotide based therapeutic
in vivo .

摘要翻译： 本发明涉及在体内靶向基于核苷酸的治疗剂的解毒剂低聚化合物（寡聚体），从而提供一种控制体内基于核苷酸的治疗剂的生物利用度和因此的治疗活性和/或副作用的方法。

公开(公告)号：EP2456870A1

公开(公告)日：2012-05-30

申请号：EP10726132.3

申请日：2010-06-30

申请人： Santaris Pharma A/S

发明人： STRAARUP, Ellen Marie ,  NIELSEN, Niels Fisker ,  LINDHOLM, Marie ,  ELMÉN, Joacim

IPC分类号： C12N15/113 ,  A61K31/712 ,  A61K31/713 ,  A61P9/10

CPC分类号： C12N15/1137 ,  C12N9/6454 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12Y304/21061

摘要： The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders.

公开(公告)号：EP2198024A2

公开(公告)日：2010-06-23

申请号：EP08803420.2

申请日：2008-08-29

申请人： Santaris Pharma A/S

发明人： MCCULLAGH, Keith ,  STRAARUP, Ellen Marie ,  NIELSEN, Niels Fisker

IPC分类号： C12N15/11

CPC分类号： C12N15/113 ,  C12N2310/11 ,  C12N2310/3231 ,  C12N2310/341

摘要： Oligonucleotides directed against the FABP4 gene are developed for modulating the expression of FABP4 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding FABP4. Methods of using these compounds for modulation of FABP4 expression and for the treatment of diseases associated with over expression of FABP4 are provided. Examples of such diseases are the metabolic syndrome, diabetes, atherosclerosis, and inflammatory states such as arthritis. The oligomer may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid (LNA) or a combination thereof.

公开(公告)号：EP2440215A1

公开(公告)日：2012-04-18

申请号：EP10724511.0

申请日：2010-06-14

申请人： Santaris Pharma A/S

发明人： NIELSEN, Niels Fisker ,  STRAARUP, Ellen Marie ,  LINDHOLM, Marie

IPC分类号： A61K31/712 ,  A61K31/713 ,  C12N15/113 ,  A61P9/10

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3521 ,  C12N2310/3533

摘要： The present invention relates to oligomer compounds (oligomers), which target APO- B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL cholesterol imbalance; dyslipidemias, e.g., familial combined hyperlipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, statin-resistant hypercholesterolemia; coronary artery disease (CAD), coronary heart disease (CHD), atherosclerosis.